Roivant Sciences Ltd.

NASDAQ (USD): Roivant Sciences Ltd. (ROIV)

Last Price


Today's Change

-0.10 (0.92%)

Day's Change

10.71 - 11.15

Trading Volume



Exchange:  NASDAQ Global Market NASDAQ Global Market

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare


CEO:  Mr. Matthew Gline Mr. Matthew Gline

Full Time Employees:  904 904

IPO Date:  2020-12-08 2020-12-08

CIK:  0001635088 0001635088

ISIN:  BMG762791017 BMG762791017

CUSIP:  G76279101 G76279101

Beta:  1.30 1.30

Last Dividend:  0.00 0.00

Dcf Diff:  14.35 14.35

Dcf:  -3.62 -3.62


Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia. The company was founded in 2014 and is based in London, the United Kingdom.


11-12 St. James’s Square,
London, SW1Y 4LB, GB

44 2074 003 347

Be the first to like this. Showing 0 of 0 comments

Post a Comment